+108.4%
FSLR vs MRNA
-70.5%
+178.9%
-60.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.0% | +0.7% | +1.3% | +2.0% |
| 7D | -0.1% | -8.2% | +8.1% | +0.5% |
| 30D | -14.0% | +125.6% | -139.6% | -24.1% |
| 3M | -16.9% | +197.1% | -214.0% | -30.8% |
| 6M | +4.7% | +148.5% | -143.8% | -10.5% |
| YTD | -20.7% | +363.3% | -384.0% | -40.2% |
| 1Y | +1.7% | +462.0% | -460.3% | -26.6% |
| 3Y | +13.1% | +26.9% | -13.8% | +3.2% |
| 5Y | +108.4% | -69.6% | +178.0% | +92.7% |
| All | +108.4% | -70.5% | +178.9% | +92.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling